Preclinical evaluation of checkpoint inhibitors in PDA therapy has been considered; however, as PDA is a non-immunogenic tumor, monotherapy blocking of the PD1/PDL1 axis or CTLA4 have not been successful [56,90]. This evidence concerns the gene PDCD1 and neoplasm.